LIDE Biotech Participates in VERIF.i®, Scientist.com’s Supplier Pre-assessment Program, to Support Continued Growth in North America and the EU
Scientist.com, the pharmaceutical industry’s leading R&D marketplace, announced today that VERIF.i®, the company’s supplier pre-assessment program, has been used to successfully complete an on-site assessment of the LIDE Biotech facility in Shanghai, China. VERIF.i was developed to help users on both sides of the Scientist.com marketplace improve quality standards and reduce indirect costs.
LIDE (Lab for Innovated Diagnosis and Experimental Therapeutics) Biotech is a translational medicine service provider that has delivered innovations in oncology translational research and immune-oncology for the past 11 years. LIDE was founded by overseas returnees Drs. Danyi Wen, Yizhun Zhu and others, with the goal of bringing together first-class research and management teams with advanced scientific backgrounds to push the frontier of translational medical research. LIDE is committed to superior research quality; in 2015, it partnered with several large pharma and biotech companies to create a PDX Consortium Board with the goal of promoting and ensuring high PDX standards across China.
“At LIDE we hold ourselves to the highest industry standards by ensuring superior quality of our facilities and the world class scientists operating them,” stated Dr. Danyi Wen, President and CEO of LIDE Biotech. “Together with other industry certifications, VERIF.i allows us to showcase our quality commitment across the industry in North America and Europe as well as in the growing Scientist.com marketplace.”
VERIF.i gives suppliers of regulated research services the opportunity to proactively communicate their standards against pre-defined criteria developed for the biopharma industry and then confirm them through independent, third-party auditors that carry out an on-site inspection. Pre-assessments help suppliers such as LIDE Biotech demonstrate their quality and capabilities, while also helping pharma and biotech customers purchase regulated services in an accelerated manner with more confidence and less risk.
“Even prior to the Covid-19 pandemic, on-site assessments of laboratories were difficult to complete owing to the high cost and intensive resource and time requirements,” stated Matt McLoughlin, SVP of Categories and Compliance at Scientist.com. “VERIF.i addresses these challenges by creating a standardized process for both customers and suppliers. It also enables suppliers like LIDE to differentiate themselves from their peers by sharing independent insight into their facilities, personnel and processes."
About LIDE Biotech
LIDE biotech is committed to accelerating translation from pre-clinical to clinical for our clients. We do this through our unique access to fresh patient samples, received daily via our close hospital partnerships across China. These relationships combined with our proprietary kits, tumor sample kit, CRC kit, MiniPDX assay kit, and K-Cell kits, LIDE’s platform gives our clients the competitive edge to save time and budget. Based on this success, LIDE has built a robust database of over 1600+ PDX, CDX, and Cell Line models which grows daily. Our CRO services can be custom tailored based on what stage of the pre-clinical oncology drug development process you’re in, including clinical biopsy collection, in vitro/in vivo studies, transcription RNA and DNA analysis, and Immuno-Oncology capabilities.
LIDE Biotech will be at the American Association for Cancer Research Annual Meeting in New Orleans from April 10 – 13. Stop by First Floor Exhibit Hall D-H, Booth # 2057.
Watch LIDE Biotech’s Director of Immuno-Oncology, Dr. Bin Xie discuss current and novel Immuno-Oncology drug evaluation methods via humanized mouse models on a Scientist.com-hosted webinar.
Scientist.com’s mission is to empower and connect scientists worldwide. By transforming the way scientific research is performed, our Science as a Service® platform accelerates discoveries that prevent and cure disease, address climate change and help secure global food and energy supplies. We combine sophisticated AI technology with white-glove Research Concierge® support to enable scientists to run more innovative experiments in less time and at lower cost.
Visit scientist.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
+1 858 455-1300 ext. 401
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Trilio Announces Technical Preview of ‘Continuous Restore,’ Delivering Cloud-Native Application Portability and Recoverability in Seconds Across Disparate Infrastructure17.5.2022 14:05:00 EEST | Press release
KUBECON + CLOUDNATIVECON EUROPE— Trilio, a leading provider of cloud-native data protection, today announced a technical preview of a new “Continuous Restore” capability that is being showcased to the cloud-native community at the KubeCon + CloudNativeCon Europe conference. Continuous Restore offers faster levels of replication, restoration and migration of data and metadata from any storage or cloud platform to another, dramatically improving recovery times for cloud-native applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005514/en/ New capability unlocks data gravity and frees data-driven organizations to quickly replicate production-grade Cloud-Native applications to any cloud in seconds. (Graphic: Business Wire) Entirely storage-, cloud- and distribution-agnostic, Trilio’s “Continuous Restore” capability will enable users to continuously stage data at multiple and heterogeneous clouds. This means that a
Forge Biologics Forms Independent Scientific and Manufacturing Advisory Board with Panel of Gene Therapy Leaders17.5.2022 14:00:00 EEST | Press release
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today the formation of an independent board of preeminent experts, a Scientific and Manufacturing Advisory Board (SMAB), to advise the Company on its gene therapy manufacturing offerings and therapeutics pipeline development. The board will serve the traditional functions of a scientific advisory board, with a distinct and strategic emphasis on manufacturing advancements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005561/en/ Credit: Forge Biologics “We are thrilled and privileged to have gathered such a renowned group of experts in gene therapy development and manufacturing to work with us to us deliver quality products to our clients, especially as we accelerate AAV production with our new 5,000L bioreactor,” said Timothy J. Miller, Ph.D., CEO, President, and Co-Founder of Forge Biologics. “The board’s guidance w
Philip Morris International Releases 2021 Integrated Report, Introducing New Sustainability Strategy and Sustainability Index17.5.2022 13:00:00 EEST | Press release
Today, Philip Morris International Inc. (PMI) (NYSE: PM) released its third annual Integrated Report, which includes an updated Statement of Purpose, a new environmental, social, and governance (ESG) framework, as well as detailed information about PMI’s strategic vision, performance, governance, and value creation model. The content was informed by a formal sustainability materiality assessment conducted in 2021. “Sustainability and business performance are fully interrelated and mutually reinforcing. Our actions—grounded in data, science, and facts—speak louder than words. PMI is committed to serving as an agent of change and advocate of positive values. We understand that our business must become a provider of effective alternatives to continued smoking for adult smokers who don’t quit. To achieve this, we are positioning ourselves at the forefront of consumer-centricity, technology, science, and innovation. With an eye to the long term, we are also expanding our business into areas
IHS Holding Limited Reports First Quarter 2022 Financial Results17.5.2022 13:00:00 EEST | Press release
IHS Holding Limited (NYSE: IHS) (“IHS Towers” or the “Company”), one of the largest independent owners, operators and developers of shared communications infrastructure in the world by tower count, today reported financial results for the first quarter ended March 31, 2022. Sam Darwish, IHS Towers Chairman and Chief Executive Officer, stated, “We had another strong quarter, with Revenue, Adjusted EBITDA, and RLFCF all above our own internal expectations, as well as consensus estimates, and we are now tracking towards the higher end of our initial 2022 revenue and adjusted EBITDA guidance, excluding the benefit from adding in our pending deal in South Africa that we expect to close imminently. Including the approximately 5,700 towers subject to the imminent completion of our pending deal in South Africa, IHS will own nearly 39,000 towers across 11 countries, making us the 3rd largest independent multinational tower company by tower count. This geographic scale helps diversify our revenu
Gasum Expands Trading Capabilities With Hansen17.5.2022 13:00:00 EEST | Press release
Hansen Technologies (ASX:HSN) is pleased to announce the expansion of its partnership with Gasum. As part of the agreement, Gasum, one of the largest energy market service providers in the Nordic region, will further extend its use of Hansen Trade to new trading solutions. The agreement builds on the encouraging benefits accrued from intraday and day-ahead trading, as well as regulating power market operations, with Hansen Trade. The new agreement will add the Intraday Trading for Asset Optimisation module, as well as the FCR + FFR module and the Market Transaction Monitoring module to the current Hansen Trade capabilities operated by Gasum – thereby allowing Gasum to leverage best-of-breed automated systems to produce beneficial outcomes, implementing zero-touch automation to replace costly, manual interventions, minimising risks in the real-time intraday market, and optimising trading operations in the Day-ahead and Intraday markets. Jouni Liimatta, Head of Trading, Gasum Ltd, commen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom